Opinion statement
A patient presenting with suspected primary central nervous system (CNS) vasculitis is often difficult to manage. Once the diagnosis is suspected, the clinical course may already be severe and warrant timely aggressive treatment with potentially toxic drugs. Definitive diagnosis is often delayed, requiring specialized tests that are only possible in certain centers and sometimes prove to be inconclusive. The need to make a confident diagnosis before starting powerful and potentially toxic immunosuppression, often conflicts with the desire to initiate timely treatment aimed at preventing irreversible neurological dysfunction. The heterogeneity and rarity of this condition is a major obstacle to conducting properly designed, double blinded, placebo-controlled studies. There is no Class I evidence for any form of treatment in these situations, and management guidelines represent expert opinion, based primarily on trials investigating therapies affecting systemic conditions with a CNS vasculitic component. Cyclophosphamide is still the main immunosuppressive drug used during active disease in combination with high dose steroids. Rituximab may be an equally efficacious, less toxic alternative, but its use is still limited due to its cost.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Lie JT. Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol. 1992;23(2):164–71.
Hajj-Ali RA. Primary angiitis of the central nervous system: differential diagnosis and treatment. Best Pract Res Clin Rheumatol. 2010;24(3):413–26.
Gotkine M, Vaknin-Dembinsky A. Neurologic manifestations of systemic immunopathological diseases. Curr Treat Options Neurol. 2012;14(3):276–92.
Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Med (Baltimore). 1968;47(5212395):337–69.
Hajj-Ali RA, Calabrese LH. Central nervous system vasculitis. Curr Opin Rheumatol. 2009;21(1):10–8.
Neel A et al. Challenging the diagnosis of primary angiitis of the central nervous system: a single-center retrospective study. J Rheumatol. 2012;39(5):1026–34.
Alba MA et al. Central nervous system vasculitis: still more questions than answers. Curr Neuropharmacol. 2011;9(3):437–48.
Scolding NJ et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain. 2005;128(Pt 3):500–15.
Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Med (Baltimore). 1988;67(1):20–39.
Berlit P. Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord. 2010;3(1):29–42.
Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology. 1989;39(2 Pt 1):167–73.
Lie JT. Classification and histopathologic spectrum of central nervous system vasculitis. Neurol Clin. 1997;15(4):805–19.
Mukhtyar C et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–7. Widely accepted guidelines which have been extrapolated for use in PACNS.
Keogh KA et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173(2):180–7.
Stone JH et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. This research establishes rituximab as a viable alternative to cyclophosphamide.
Sen ES et al. Treatment of primary angiitis of the central nervous system in childhood with mycophenolate mofetil. Rheumatology (Oxford). 2010;49(4):806–11.
Mukhtyar C et al. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S93–8.
Wilde B et al. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2011;79(6):599–612.
Faurschou M et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–5.
Black AJ et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;29(9):716–8.
Brihaye B et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S23–7.
Seror R et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis. 2007;66(3):351–7.
Disclosure
Marc Gotkine declares that he has no conflict of interest.
Adi Vaknin-Dembinsky declares no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gotkine, M., Vaknin-Dembinsky, A. Central Nervous System Vasculitis. Curr Treat Options Neurol 15, 367–374 (2013). https://doi.org/10.1007/s11940-013-0227-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-013-0227-8